The Best Treatment Option After Surgery for Triple-Negative Breast Cancer

Triple-negative breast cancer is distinguished by the absence of estrogen receptors (ER) and progesterone receptors (PR) on cancer cell surfaces, and the absence of overexpression of HER2 receptors. It is a subtype of breast cancer and accounts for around 15% of all breast cancers. Compared with other breast cancers, it tends to divide, multiply and metastasize more quickly, and is therefore more sensitive to chemotherapy. In addition, around 11% of triple-negative breast cancers are associated with hereditary cancer genes (BRCA 1-2) and tend to occur at younger ages.
If triple-negative breast cancer is detected early, the standard treatment is surgery followed by adjuvant (protective) chemotherapy. On August 13, 2020, JAMA Oncology published a comprehensive study called PATTERN, according to which the best adjuvant treatment for this cancer appears to be the carboplatin plus paclitaxel combination chemotherapy regimen.
This randomized (random patient enrollment) phase-III clinical trial was conducted at multiple centers in China.
Why the study matters
The GeparSixto and CALGB 40603 studies had previously demonstrated the effectiveness of platinum chemotherapy drugs in neoadjuvant (preoperative) and palliative (advanced-stage) treatment of patients with triple-negative breast cancer, and they had entered routine practice with recommendations from international guidelines. PATTERN is the first study to clearly demonstrate the adjuvant effectiveness of platinum chemotherapy drugs and produce data with a high potential to change clinical practice in guidelines.
Study details
- Patients were enrolled between July 2011 - April 2016.
- The median follow-up period was 62 months.
- The study inclusion criteria were:
- being a woman aged 18-70,
- having operable triple-negative breast cancer and not having previously received neoadjuvant chemotherapy,
- having axillary lymph node metastases detected during surgery or a tumor larger than 1 cm,
- an overall performance score of 0-1,
- and adequate blood, kidney and liver values.
Results
- The study enrolled 647 patients who met the criteria above. 325 patients entered the "6 cycles of carboplatin-paclitaxel" arm; 322 patients entered the "3 cycles of FEC, 3 cycles of docetaxel" arm.
- There were no deaths due to chemotherapy side effects in either arm. The groups did not differ in chemotherapy completion rates or the need for dose reduction.
- In terms of rates of regional and distant metastasis or recurrence (cancer returning), the carboplatin-paklıtaksel arm was significantly superior to the standard chemotherapy arm, FEC-docetaxel.
- The 5-year disease-free survival rates were 86.5% in the carboplatin-paklitasel arm and 80.5% in the FEC-docetaxel arm. Carboplatin-paklitasel was found to reduce the risk of recurrence/metastasis by 35% compared with standard treatment.
- The 5-year overall survival rate was 93.4% in the carboplatin-paklitasel arm and 89.8% in the FEC-docetaxel arm.
In conclusion, these data strongly support platinum chemotherapy becoming standard in the adjuvant treatment of triple-negative breast cancer as well, and are of a nature to change clinical practice.
Sources
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer
A Phase 3 Randomized Clinical Trial.
JAMA Oncol. Published online August 13, 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.